Australian Antitrust Agency OKs Baxter's $4B Gambro Buy

Law360, New York (September 5, 2013, 5:04 PM EDT) -- Australia's antitrust regulator on Wednesday said it won't oppose Baxter International Inc.'s $4 billion bid for Swedish dialysis product maker Gambro AB since Baxter plans to sell part of its unit that offers acute kidney failure treatments.

Baxter and Gambro are the largest two of three continuous renal replacement therapy product suppliers in Australia, and the Australian Competition and Consumer Commission harbored concerns that the proposed acquisition could cause higher prices for CRRT therapy in the country's hospitals, similar to hesitations the European Commission had voiced...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.